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Abstract
Pancreatic necrosis complicating severe acute pancreatitis is a
challenging scenario in contemporary critical care practice; it
requires multidisciplinary care in a setting where there is a relatively
limited evidence base to support decision making. This commentary
provides a concise overview of current management of patients with
infected necrosis, focusing on detection, the role of pharmacologic
intervention, and the timing and nature of surgical interventions.
Fine-needle aspiration of necrosis remains the mainstay for
establishment of infection. Pharmacological intervention includes
antibiotic therapy as an adjunct to surgical debridement/drainage
and, more recently, drotrecogin alfa. Specific concerns remain
regarding the suitability of drotrecogin alfa in this setting. Early
surgical intervention is unhelpful; surgery is indicated when there is
strong evidence for infection of necrotic tissue, with the current
trend being toward ‘less drastic’ surgical interventions.
Introduction
Pancreatic necrosis complicating severe acute pancreatitis is
a challenging scenario in contemporary critical care practice.
Patients are often relatively young (the median age was
55 years [range 19–74 years] in a recent cohort report [1])
and postrecovery quality of life should be good [2], and so
there is much to strive for. However, length of stay can be
prolonged, and the evidence guiding treatment is limited and
contradictory in nature. Crucially, care for these patients
involves close multidisciplinary cooperation because the
margin for therapeutic error in decision making in relation to
the timing and nature of intervention is small.
It is generally accepted that death from acute pancreatitis has
a bimodal temporal distribution; early deaths are related to
multiple organ failure [3] and may in particular affect elderly
patients, in whom decisions on thresholds for intervention
may influence treatment and outcome. Death from infected
necrosis or the sequelae of peri-pancreatic sepsis is
responsible for most late mortality [4]. Management of this
group of patients is complex, but there has been a recent
increase in the scope of available therapeutic options.
Recent developments can be categorized into those directed
at diagnosing infected necrosis, new pharmacological
interventions and recent surgical trends.
Diagnosis of infected necrosis
The path finding study conducted by Beger and coworkers
[5] showed that the proportion of patients with pancreatic
necrosis with evidence of bacterial colonization increased as
the disease progressed. Infection of peripancreatic necrosis
is relatively uncommon during the first 10 days of illness, and
accordingly there is little to be gained by attempts at
radiologically guided aspiration of fluid at this stage. Fine-
needle aspiration of peripancreatic necrosis to look for
evidence of infection comes into play between days 10 and
14 of the illness and, if negative, aspirates should be
repeated at regular intervals thereafter. The area to be
targeted requires specific attention to detail. In the study
conducted by Beger and coworkers [5], fine-needle
aspiration was directed at peripancreatic necrosis rather than
at intra-abdominal fluid collections. If patients have both, then
they should be separately sampled and labelled as such.
Newer methods used for detection of infected necrosis
include measurements of biochemical markers such as
calcitonin precursors [6]. Procalcitonin is the 116 amino acid
precursor of calcitonin; it is released from neuroendocrine
cells and detected in high concentrations in serum during
severe bacterial or fungal infections [6]. Elevated levels of
procalcitonin correlate with disease severity, and there is
some evidence of an association between procalcitonin
levels and infection of necrosis. Use of genetic analytical
techniques to quantify circulating bacteria derived gene
products in plasma is interesting but not an established
method [7].
Diagnosis of pancreatic infection requires vigilance. Patients
receiving critical care are at high risk for developing infected
necrosis and require serial imaging and aspiration of
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necrosis. It should be borne in mind that radiological
(computed tomographic) findings such as the presence of
gas can indicate infection. It should also be remembered that
a clinical diagnosis of infected necrosis based on fever,
leucocytosis and other markers of sepsis without substantive
proof of infection of necrosis can frequently be incorrect, and
in turn may lead to potentially unnecessary surgery [1].
Pharmacological intervention in infected
necrosis
There remains no specific pharmacological treatment for
infected necrosis, and the mainstay of treatment is drainage
or debridement. Antibiotic therapy has a role to play as an
adjunct to debridement/drainage. More recently, based on
the results of the PROWESS (Recombinant human protein C
Worldwide Evaluation in Severe Sepsis) trial [8], drotrecogin
alfa (recombinant human activated protein C) has been used
in patients with sepsis. In an experimental model of acute
pancreatitis, administration of drotrecogin alfa resulted in
improvement in markers of tissue injury and inflammation [9].
However, there are specific concerns relating to the risk for
haemorrhage. More pragmatically, when criteria for use of
drotrecogin alfa are met in a patient with pancreatitis, it could
be argued that the thrust of treatment should be to find and
treat any intra-abdominal focus of infection [10-12].
Timing and nature of surgical intervention
Although these issues remain controversial, some consensus
regarding the timing of surgical intervention is emerging. Early
surgery for pancreatic necrosis is unprofitable because areas
of necrosis will not yet have ‘demarcated’ and the risk for
haemorrhage is high [13]. In practice, early laparotomy in
severe acute pancreatitis can be justified in those individuals
in whom there is concern about coexisting pathological
processes, such as colonic ischaemia. Thus, a practical
management plan emerges; early pancreas-directed
intervention is unprofitable, and surgery has a role to play only
when it is needed to rule out coexisting disease.
At the risk of adding complexity to this algorithm, we must
consider the current trend toward measurement of intra-
abdominal compartment pressure. An observational study of
293 patients with severe acute pancreatitis [14] demon-
strated that early onset of organ dysfunction (within 72 hours
of onset of symptoms) was associated with intra-abdominal
hypertension (defined as intra-abdominal pressure
>15 mmHg) in 78% of patients. This led to speculation about
whether there is a role for early surgical intervention in the form
of a ‘decompressing’ laparotomy for raised intra-abdominal
pressure [15,16]. A practical compromise is required here.
‘Decompressing’ laparotomy in patients without prior surgery
carries a high risk for postoperative evisceration, intra-
abdominal infection and colonization of previously sterile
pancreatic necrosis, and cannot be generally recommended.
Similarly, insertion of abdominal drains seems illogical. Intra-
abdominal hypertension is due to fluid sequestration as a
result of capillary endothelial injury, and thus there will be
interstitial fluid in addition to free intra-peritoneal fluid. Simple
drainage of fluid collections is unlikely to be of benefit.
However, in selected cases, in particular where diaphrag-
matic splinting may compromise ventilation, an argument can
be made for decompression.
What of the nature of intervention? Our group demonstrated
that ‘traditional’ surgical open necrosectomy, involving a long
bisubcostal incision, extensive intra-abdominal mobilization
and multiple drains, was a major surgical undertaking and
associated with a worsening in organ failure scores during
the immediate postoperative period [1]. In light of this, there
has been a movement toward less drastic surgery. The
Glasgow group pioneered minimally invasive necrosectomy
[17] – following a radiologically placed guide wire (under
general anaesthesia) with a urological scope to effect
debridement under irrigation. Various permutations of this
procedure have been reported, and there is as yet no
consensus on descriptive terminology or technique.
Again, a pragmatic policy is required. Infected necrosis in
which there is a predominance of solid and semisolid tissue
in the peripancreatic area requires surgical debridement. The
available evidence suggests that ‘less drastic’ surgery (i.e. a
mildine laparotomy, debridement, drainage and placement of
a feeding jejunostomy) is a safe and adequate option [18]. To
maintain a balanced perspective, it must be acknowledged
that the minimally invasive procedures may be equally
effective, but these are critically dependent on the expertise
of the operator. Equally importantly, in those patients with
pancreatic necrosis with a predominantly liquid collection, a
pancreatic abscess can often be managed by radiological
drainage (which adheres to the principles outlined above)
and thus avoid surgery. In all cases repeated intervention may
be indicated, and the minimum requirement for contemporary
care is the availability of radiological, critical care and
pancreatic surgical expertise.
Conclusion
Contemporary critical care management of the patient with
pancreatic necrosis complicating acute pancreatitis is an
area of relatively rapid change. Newer methods for detecting
infection, new pharmacological interventions and more
sophisticated surgery are all changing the face of care for this
complex disease. These developments should not obscure
the importance of the underlying principle that patients with
infected necrosis require debridement/drainage of their intra-
abdominal focus of sepsis.
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